RT Journal Article
SR Electronic
T1 Adipocyte JAK2 mediates aging-associated metabolic liver disease and progression to hepatocellular carcinoma
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 681809
DO 10.1101/681809
A1 Kevin C. Corbit
A1 Camella G. Wilson
A1 Dylan Lowe
A1 Jennifer L. Tran
A1 Nicholas B. Vera
A1 Michelle Clasquin
A1 Aras N. Mattis
A1 Ethan J. Weiss
YR 2019
UL http://biorxiv.org/content/early/2019/06/24/681809.abstract
AB Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are liver manifestations of the metabolic syndrome and can progress to hepatocellular carcinoma (HCC). Loss of Growth Hormone (GH) signaling is reported to predispose to NAFLD and NASH through direct actions on the liver. Here, we report that aged mice lacking hepatocyte Jak2 (JAK2L), an obligate transducer of Growth Hormone (GH) signaling, spontaneously develop the full spectrum of phenotypes found in patients with metabolic liver disease, beginning with insulin resistance and lipodystrophy and manifesting as NAFLD, NASH and even HCC, independent of dietary intervention. Remarkably, insulin resistance, metabolic liver disease, and carcinogenesis are prevented in JAK2L mice via concomitant deletion of adipocyte Jak2 (JAK2LA). Further, we demonstrate that GH increases hepatic lipid burden but does so indirectly via signaling through adipocyte JAK2. Collectively, these data establish adipocytes as the mediator of GH-induced metabolic liver disease and carcinogenesis. In addition, we report a new spontaneous model of NAFLD, NASH, and HCC that recapitulates the natural sequelae of human insulin resistance-associated disease progression. The work presented here suggests a attention be paid towards inhibition of adipocyte GH signaling as a therapeutic target of metabolic liver disease.